Neurodevelopmental assessment at 24 months in infants with esophageal atresia: A prospective cohort study
Journal of Pediatric Gastroenterology and Nutrition · 2026-06 · 82 (6) · 1386-1393
DOI: 10.1002/jpn3.70406 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 19.03.2026. Verfasst von Julia Tagmouti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology and CRMR CRACMO, APHP, Necker-Enfants Malades University Hospital, Paris, France. Hauptthemen laut MEDLINE: Child Development, Developmental Disabilities, Esophageal Atresia, Neurodevelopment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: None, ARFEN.
Abstract (Originalsprache)
Objective
To evaluate neurodevelopment at 24 months in infants surgically treated for esophageal atresia (EA), using the ages and stages questionnaire (ASQ), and identify perinatal and early‐life factors associated with developmental delay.
Methods
Infants with EA were prospectively enrolled in a structured multidisciplinary follow‐up program. Total ASQ scores ≤185 were considered indicative of significant neurodevelopmental delay, while scores >220 reflected reassuring neurodevelopment. Five skill domains (communication, gross motor skills, fine motor skills, problem solving, and social skills) were also assessed. Clinical, surgical, and growth data were analyzed to identify associated risk factors.
Results
Of the 74 infants included, 13 patients (18%) had an ASQ score ≤185. Lower ASQ scores were significantly associated with prematurity, prolonged hospitalization, multiple surgeries, poor weight gain at 1 and 2 years, and feeding disorders. After adjusting for gestational age and genetic anomalies, prolonged hospitalization remained associated with lower ASQ scores, and higher weight‐for‐age at 1 and 2 years with better ASQ scores. Communication and social skills were the most severely affected, with approximately 80% of infants in the ASQ ≤ 185 group scoring below –2 standard deviations.
Conclusion
Although most children with EA demonstrated normal development at 2 years, a minority experienced significant delays, especially in communication and social skills. Early screening and targeted multidisciplinary follow‐up are essential to support optimal outcomes in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neonatology and CRMR CRACMO, APHP, Necker-Enfants Malades University Hospital, Paris, France.
- UFR de Médecine, Paris Cité University, Paris, France.
- Department of Pediatric Surgery, Urology and Transplantation, Necker-Enfants Malades University Hospital, APHP, Paris, France.
ORCID-Profile: Julia Tagmouti
Förderung
- None
- ARFEN
Zitieren
APA
Tagmouti, J., Midavaine, M., Sartorius, V., Vinit, N., Leroy-Terquem, E., Beaudoin, S., Kermorvant-Duchemin, E., Rousseau, V., & Lapillonne, A. (2026). Neurodevelopmental assessment at 24 months in infants with esophageal atresia: A prospective cohort study. Journal of Pediatric Gastroenterology and Nutrition, 82(6), 1386-1393. https://doi.org/10.1002/jpn3.70406
Vancouver
Tagmouti J, Midavaine M, Sartorius V, Vinit N, Leroy-Terquem E, Beaudoin S, et al. Neurodevelopmental assessment at 24 months in infants with esophageal atresia: A prospective cohort study. Journal of Pediatric Gastroenterology and Nutrition. 2026;82(6):1386-1393. doi:10.1002/jpn3.70406
BibTeX
@article{Tagmouti2026,
author = {Tagmouti, Julia and Midavaine, Manon and Sartorius, Victor and Vinit, Nicolas and Leroy-Terquem, Elise and Beaudoin, Sylvie and Kermorvant-Duchemin, Elsa and Rousseau, Véronique and Lapillonne, Alexandre},
title = {Neurodevelopmental assessment at 24 months in infants with esophageal atresia: A prospective cohort study},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {82},
number = {6},
pages = {1386--1393},
doi = {10.1002/jpn3.70406}
}
EUVIMED